Immunoparalysis After Pancreaticoduodenectomy

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

December 1, 2026

Conditions
Pancreatic Ductal Adenocarcinoma (mPDAC)Pancreatic Head TumourPancreatic Fistula
Interventions
DIAGNOSTIC_TEST

mHLA-DR analysis

"mHLA-DR analysis will be realized on Cyto-Chex® BCT anticoagulant tubes (5mL). Each sample will be transported and centralized at the Immunology Laboratory of Edouard Herriot Hospital and analyzed by flow cytometry.~Samples will be collected :~* The day of surgery before intervention~* The day of surgery after intervention~* At postoperative day one~* At postoperative day two~* At postoperative day three~* At postoperative day four~* At postoperative day five~* At postoperative day seven"

Trial Locations (4)

69003

Julie PERINEL, Lyon

69004

Xavier MULLER, Lyon

69008

Aurélien DUPRE, Lyon

69495

Jean-Christophe LIFANTE, Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT07144917 - Immunoparalysis After Pancreaticoduodenectomy | Biotech Hunter | Biotech Hunter